| 3.32 -0.38 (-10.27%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.02 |
1-year : | 5.76 |
| Resists | First : | 4.3 |
Second : | 4.94 |
| Pivot price | 3.93 |
|||
| Supports | First : | 3.27 |
Second : | 2.72 |
| MAs | MA(5) : | 3.83 |
MA(20) : | 4.05 |
| MA(100) : | 4.73 |
MA(250) : | 5.49 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 21 |
D(3) : | 34.1 |
| RSI | RSI(14): 27.2 |
|||
| 52-week | High : | 10.36 | Low : | 3.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TKNO ] has closed below the lower bollinger band by 19.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 23.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.8 - 3.84 | 3.84 - 3.86 |
| Low: | 3.21 - 3.25 | 3.25 - 3.27 |
| Close: | 3.27 - 3.34 | 3.34 - 3.38 |
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Thu, 08 Jan 2026
Alpha Teknova, Inc. (TKNO) Stock Analysis: Exploring A 120% Potential Upside Opportunity - DirectorsTalk Interviews
Wed, 12 Nov 2025
Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.00 - simplywall.st
Sat, 08 Nov 2025
Alpha Teknova, Inc. (NASDAQ:TKNO) Analysts Are Pretty Bullish On The Stock After Recent Results - Yahoo Finance
Wed, 05 Nov 2025
Alpha Teknova Inc (TKNO) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Tue, 28 Oct 2025
Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewswire
Thu, 25 Sep 2025
Alpha Teknova, Inc.'s (NASDAQ:TKNO) P/S Is Still On The Mark Following 27% Share Price Bounce - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 54 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 10.8 (%) |
| Held by Institutions | 84.5 (%) |
| Shares Short | 1,770 (K) |
| Shares Short P.Month | 2,040 (K) |
| EPS | -0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.36 |
| Profit Margin | -45.8 % |
| Operating Margin | -38.5 % |
| Return on Assets (ttm) | -9.8 % |
| Return on Equity (ttm) | -22.8 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 0.23 |
| Sales Per Share | 0.74 |
| EBITDA (p.s.) | -0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -10.07 |
| PEG Ratio | 0 |
| Price to Book value | 2.44 |
| Price to Sales | 4.46 |
| Price to Cash Flow | -19.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|